ArticleFrontiers in pediatrics2026
Age-stratified safety signal mining of ADHD medications in pediatric populations using the FAERS database (2014-2024): a pharmacovigilance study using multi-method disproportionality analysis.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric attention-deficit/hyperactivity disorder (ADHD) medications have been analyzed in the FDA Adverse Event Reporting System (FAERS), yet systematic age-stratified signal profiling under ICH E11(R1) developmental categories, covering the recently approved agents viloxazine and serdexmethylphenidate, remains unreported. Methods: We performed a retrospective disproportionality analysis of pediatric (age <18 years) FAERS reports, 2014Q1-2024Q4, after FDA-standard three-step deduplication. Ten active ingredients (eight in the main analysis, two in a new-drug branch) were identified. Reporting odds ratios (ROR), proportional reporting ratios (PRR), information components (IC, Bate 1998 uniform prior), and empirical Bayesian geometric means (EBGM, DuMouchel 1999) were computed. A signal was classified as Strong when positive across all four methods. Seven prespecified sensitivity analyses were conducted. Results: Among 15,301 pediatric ADHD cases, 100 Strong signals were identified (71 in adolescents, 29 in children). Conclusion: Distinct age-specific safety signals emerged for ADHD medications, with dextroamphetamine-PRES warranting targeted pharmacovigilance attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.